Clinicopathological analysis showed that the expression of PARD3 was positively associated with the expression of SHH signalling molecules, which together could be used to stratify HCC patients into two clusters with different clinical characteristics and overall survival outcomes. This evidence concerns the gene SHH and hepatocellular carcinoma.